6.5 C
New York
Monday, December 6, 2021

Dementia Drug: Mirtazapine is no more than a placebo, may increase death risk

Must Read

A “powerful, maybe even frightening” woman wearing diadem reappears after 4,000-years

A meticulous scientific reproduction exposes the ancient people of El Argar's facial traits. The...

Genetic evidence reveals surprising new consequences of Vitamin D deficiency

Vitamin D provides a natural supply for one of the hormones important to our systems, particularly the...

Review of COVID-19 Vaccine-induced Myocarditis in US Kids and Young Adults

Myocarditis is a rare but dangerous heart muscle inflammation. It can weaken the heart and interfere with...
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

A new study, published by the University of Plymouth’s researchers in The Lancet, found that antidepressant mirtazapine didn’t show any positive results for people suffering from dementia.

Agitation is a common dementia symptom that is characterized by inappropriate verbal, vocal, or motor activity, as well as physical and verbal violence. Non-drug patient-centered care should be tried initially, but if this does not work, physicians may resort to a drug-based option.

Mirtazapine has been commonly recommended since antipsychotics have been shown to increase death rates in patients with dementia, as well as other negative consequences. This study was meant to add to the body of evidence surrounding its efficacy.

The study, sponsored by the National for Health Research (NIHR), enrolled 204 adults with probable or suspected Alzheimer’s disease from 20 sites across the UK, randomly assigning half to mirtazapine and the other half to placebo. The trial was conducted in a double-blind style, which means that neither the researcher nor the research subjects knew what they were taking.

The results showed that the mirtazapine group had no less agitation than the control group after 12 weeks.

There were also seven additional deaths in the mirtazapine group (compared to one in the control group) by week 16, with analysis indicating that this was of marginal statistical significance.

Source: The Lancet

Image Credit: Getty

You were reading: Dementia Drug: Mirtazapine is no more than a placebo, may increase death risk

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -